Member Info for Doc.Daneeka

"There is a fire. What difference does it make if influenza, Covid, RSV or a cold put you there? Your immune system needs urgent back up and SNG001 is going to help fight the fire. "
Champagne on me if it happens gunto. Lots of it. But this is not how medical science works. You do trials for all of them oand start with the one you have the best shot at - which might let someone give you a trial for everything else.
It's never happened before - but you think they're gonna change the whole rule book for a 14p a share company that no-one has heard of.

Size - yeah we should ahve a better than 20-30% chance - but that's where i put the odds. Subjectively.

Size82 I know you're asking Gunto but your post elucidates some of the reasons why the multi virus trial idea is a non starter. Forget about the numbers of patients for a moment - but yes circa 1k is the region RM has said is the number needed. You'd need a seperate protocol for every drug & some kind of pre-trial dosing study for things we've never even done lab tests for. This whole idea began with the company banging on about broad sprectrum when it thought the Covid chance had gone - and on here people like Mani and others misunderstanding what Stacey said about the ultimate intention for STRIVE to be a multi virus platform. RM encouraged it. In his Proactive interview he didn't even say the word Sprinter but talked instead about resuming the company's long held ambition to become a BS therapy.
Tommy's Pfizer - or one of the other megatrons could possibly talk NIH into a single drug multiple virus trial but there is zero chance that a company of the size and profile of Synairgen might achieve this - without ever having a single word of encouragement for either of the most recent sets of results. It's fantasy island.
They were waiting for us to stand up our P2 or smash Activ 2 and when we didn't do either they said nothing. Didn't even bother to run the detailed numbers on Activ ". Which tells us that nobody considers SNG to have even a slim chance of becoming the blockbuster drug we originally hoped it might become.
Strive can still start to build something back - but only for Covid and the chances have to realistically be around 20-30% now that we are selected
Throughout this pandemic important people have talked about the things they think might have promise or offer a chance of success. This has never happened with SNG - either here or in the States. Nobody in NIH has ever said - "hey - we like the look of SNG " Stacey Adam paid attention to the drugs NIH were still interested in in the Grand Rounds presentation. Fpor A2 she spent time discussing Brii but not only did she not mention SNG - she didn't even include us in the slideshow. The single drug in any of the arms of the trial that failed to make the graphics board
28.35. Activ 2 summary.
https://rethinkingclinicaltrials.org/news/grand-rounds-july-15-2022-overview-of-accelerating-covid-19-therapeutic-interventions-and-vaccines-activ-public-private-partnership-and-lessons-learned-stacey-j-adam-phd/

Now we're in a new landscape. Almost all of the monoclonals - that amazing hamster juice that worked so well until Omicron's arrival - are gone. Protease inhibitors in hospital are the new hope. But even though Omicron has given the world reason to believe the worst is behind us, we're still just a Chinese cough and splutter from a variant that evades everything and takes us back to December 2019. So maybe SNG has a chance again. It worked for inpatients when there was nothing. Last man standing says they should be looking at the drug again. It's still entirely a Covid

If you put on the full Mani evening gown Doc83 you might imagine Horby has wind of something from across the pond and has put us forward for this.

click "Event overview" to see the UK companies attending

Arab Health 2023 is on now. Halfway through and we're not there. 2 other events listed for later in the year. The next in Basel in March - we're not listed for that eithe. They haven't chosen the reps for the Boston event in June

https://eu.eventscloud.com/website/9999/events/

Your other point about affordability Elsol is absolutely spot on too - despite the hundreds of posts describing the cost of emegency beds here and particularly in the US and deriding those of us who though £2-£3k per treatment might be off-putting.
When SG016 landed on July 20th 2020 the timing as well as the topline figure seemed incredible, but Recovery had announced it's 30% Dexa result almost exactly a month earlier on June 21st.
10 days of Dexa tabs- or infusion for those beyond helping themselves -patent free and costing pennies. The UK's gift to the world. SNG obviously shouldn't have been compared to this - but it probably was.

Not even slightly annoyed at the board - a little irritated by your constant need to butt in with misleading "data"
I'll keep calling bollo.cks on the usual suspects or nonsense that suggests signs when none exist and i'll continue to applaud the real finds that are the lifeblood of this bb.
At the moment we're still waiting and having made my position clear on the SPAC fantasy - posted with consumate erudition and relentless enthusiasm by a long term investor who having kept utterly silent for nearly 3 years is now a gushing fount, I'll say no more on it except that I suspect Ndn has rejoined and once again with an agenda.

Elsol there are many tragedies of this drug's prolongued absence from the world's covid wards - but undoubtedly the first great miss was not being offered every form of assistance by the Govt immediately following SG016's explosive arrival. Partly it is clear that the company wanted to find its own path but if Recovery had offered an immediate large trial and all the resouces possible, the drug could have bneen approved and in hospitals by the summer of 21.

It's a silly distraction from the even sillier SPAC Chat.

This thread is celebrating a bit of good news - one that most certainly raises the profile of the company and the drug at a really important time.
Keep your dromedaries and spac nonsense inside their own threads.

Come off it Fruits you're being ludicrously pedantic. A disease can have a 90% fatality rate but if nobody catches it and MERS really is almost impossible to catch without being a camelherder - or a camel farmer's girlfriend then it's not a danger to anyone.
Titania was suggesting - as she did during the World Cup - that Mers is or might be a current danger. It just isn't - and if you accuse me of picking a low period - your 2012 headline spins a really false narrative, as the total global deaths from 2012 to 2022 is 935, which means just 135 extra deaths in the 10 years after the outbreak began. 13 and a half a year, and all but 99 of the deaths in Saudi Arabia.

"From April 2012 till December 2022, a total of 2603 laboratory-confirmed cases of
Middle East respiratory syndrome (MERS) were reported globally, with 935 associated
deaths at a case-fatality ratio (CFR) of 36%. The majority of these cases were reported
from Saudi Arabia, with 2194 cases and 854 related deaths

Don't get the hump Tiitania but you're a hoot. Glad you're still keeping an eye on it for us though. Remembering that you have to French kiss a camel to catch it and drink 20 pints of infected camel milk

"Since the beginning of 2022, and as of 9 January 2023, six MERS-CoV cases have been reported in Saudi Arabia (3), Qatar (2), and Oman (1), including one death. "
https://www.ecdc.europa.eu/en/middle-east-respiratory-syndrome-coronavirus-mers-cov-situation-update

All good news is good news. Well done to the team and to Theodora Harold too - she had the Crescendo gig before joining Synairgen so she's backed 2 winners. (albeit Crescendo is a way ahead of SyN and they DO have a big pharma partner )

That's interesting gunto. The protocols will all be tailor made for sure, but if they were just admitting SNG based on the DD you're right that it wouldn't be this complicated. It would be incredibly bold. I was hoping for STRIVE for C19 but if you're offering it for some of the others too I'll take it. Sure we all will.

My honest feeling though is that they'd need the first authorisation to set everything else in train. Just as drugs like Remdes and Paxlovid are getting trialed in other spaces and stages - once the door is open you can walk through to anywhere you want to get to

We'll see. STRIVE is going to be a broad trialling arena - for many respiratory infections is what Stacey said not an arena trialling drugs against multiple infections simultaneously.

There's a growing body of evidence that SNG has - that no other drug has to make it such a candidate - without question. A kind of antibiotic level of treament which was mentioned i think y ~rick Bright recently - but it's a long way from all thse dots and arrows and an actual simultaneous trial.
There is enough safety and efficacy for instance to allow SNG to be administered to every worsening Covid patient, with the right predertermined factors - but is there the general efficacy or safety to allow any health authority to agree to a broad trial for every other respiratory patient in similar difficulty ? I mean that's hellish difficult - even just in terms of dosing as the twice posted Synairgen mission abstract admits.
This is not for Td of course. his 2 minutes are up.

TommyD you're a trier - still full of the same shi.t after all this time. Do me a favour and save those 2 minutes. Stick me in your bin

You've embarrassed yourself more with each subsequent post today. Soldiering on long after your girlfriend has departed for Beachy Head. Pure rampy gold

"As we are a broad spectrum drug the next trial will likely cover a wider range of viruses of which there are millions of cases each year. "

"There’s around 17 billion respiratory infections each year globally
I think we’ll find a few for a trial "

"I guess if they were JV with a company the size of Pfizer they’d cope ok? "

Optiion1 is the only possibility that doesn't lead to the end of Synairgen. In fact it's the only possibility - full stop.
#1 PT for Covid - tick
#2 Who would JV with a company that needs a trial that costs more than the company is worth.
#3 Likewise with these phantom spaccy investors. How could the money Geckos see more in the medical data than the dozens and maybe 100s of big pharma specialists who've run the scientific numbers on SNG and decided it's not worth the punt. Spacman's theory relies entirely on a coalition of moneymen having more faith in data they have not a clue about than their equally geeky scientific cousins. As if all those clever guys and dolls at JPM23 are just chucking the dice at the wall and hoping for snake eyes.

Size yes - all of the rest

Yeah Pfizer. Good shout. $248.5b mcap company Pfizer could certainly JV it. But what do you think they might want for the $50m investment though Tommy ? 10% of future sales ? 15% ?

Delusional - the pair of you. Posting a mission statement describing a drug so powerful and efficacious that every respiratory patient needs to be given it, but a company that failed its best chance to begin the process and in that endeavour blew it's resources to such an extent that it has no possibilty of funding any further trialing
What RM would like to happen and what is happening and has happened are so very far apart it's just ridiculous to hear you both sitting in your SNG hoodies singing the company song. With not one word ever from anyone important, anywhere since P2 in support of the drug or the company except maybe Rick Bright in his paid-for appearance when he wasn't allowed to say the name.
I'm here for STRIVE. We deserve to be on STRIVE. If we don't get onto it the curtain will come down. We probably won't get onto it because nobody - not even Stacey Bright remember in her summation of The Activ program, when SNG was the only drug missing friom the slideshow )- has heard of us.

Tommyd I responded specifically to this line "As we are a broad spectrum drug the next trial will likely cover a wider range of viruses of which there are millions of cases each year. "
which is utter bollo.xios

Brand - no question that's what the company want to do, and even less doubt that it would be of great benefit to mankind if it were achievable. The trouble is that nobody else seems to share this vision. If anyone else really believed SNG was THE ONE - it would have been snapped up or supported months or years ago.
Quoting the company's own statements does not equate to evidencing an argument.

Zero chance our next trial will " likely cover a wider range of viruses " Wishful thinking of the most extreme variety supported by zero evidence. No such multi disease platform trial exists or ever has existed and it would cost far beyond the £35m Sprinter sucked up for the company to do it itself ( even if the company's treasure chests contained more than just the money for wages and conferences )
If Sprinter had succeeded there'd be gold, prestige and support for such a revolutionary - indeed unique trial design - but as it did not, this glib prediction is arrant nonsense
Got to hand it to you though Tommy - here we all are - desperate for one little P3 to add the extra few hundred we needed to get SNG into hospitals for Covid - but when you close your eyes you see billions arriving in hospital with a respiratory infection being led to their bed and handed their neb.